Cumulative community-level lead exposure and pulse pressure: The normative aging study

Environmental Health Perspectives

Volumn 115, Issue 12, 2007, Pages 1696-1700

  Perlstein, Todd ^a   Weuve, Jennifer ^b   Schwartz, Joel ^b   Sparrow, David ^c,d   Wright, Robert ^a,b,e   Litonjua, Augusto ^a   Nie, Huiling ^a,b   Hu, Howard ^a,b,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Aging; Epidemiology; Human; Lead exposure; Pulse pressure

Indexed keywords

LEAD;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; BLOOD; BLOOD PRESSURE; CHEMISTRY; COHORT ANALYSIS; DEMOGRAPHY; DRUG EFFECT; ENVIRONMENTAL EXPOSURE; HUMAN; LEAD POISONING; MALE; MIDDLE AGED; NONPARAMETRIC TEST; PHYSIOLOGY; TIBIA;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AGING; BLOOD PRESSURE; COHORT STUDIES; ENVIRONMENTAL EXPOSURE; HUMANS; LEAD; LEAD POISONING; MALE; MIDDLE AGED; RESIDENCE CHARACTERISTICS; STATISTICS, NONPARAMETRIC; TIBIA;

EID: 38749150662     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.10350     Document Type: Article

References (55)

1. Abramson J. L, Weintraub WS, Vaccarino V. 2002. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 39:197-202.
2. Barry P. S, Mossman DB. 1970. Lead concentrations in human tissues. Br J Ind Med 27:339-351.
3. Burger D. E, Milder FL, Morsillo PR, Adams BB, Hu H. 1990. Automated bone lead analysis by K-x-ray fluorescence for the clinical environment. Basic Life Sci 55:287-292.
4. Cheng Y., Schwartz J, Sparrow D, Aro A, Weiss ST, Hu H. 2001. Bone lead and blood lead levels in relation to baseline blood pressure and the prospective development of hypertension: the Normative Aging Study. Am J Epidemiol 153:164-171.
5. Domanski M., Norman J, Wolz M, Mitchell G, Pfeffer M. 2001. Cardiovascular risk assessment using pulse pressure in the first National Health and Nutrition Examination Survey (NHANES I). Hypertension 38:793-797.
6. Drasch G.A. 1982. Lead burden in prehistorical, historical and modern human bones. Sci Total Environ 24:199-231.
7. Farmand F., Ehdaie A, Roberts CK, Sindhu RK. 2005. Lead-induced dysregulation of superoxide dismutases, catalase, glutathione peroxidase, and guanylate cyclase. Environ Res 98:33-39.
8. Ferris B.G. 1978. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 118:1-120.
9. Franklin S. S, Gustin W, Wong ND, Larson MG, Weber MA, Kannel W. B, et al. 1997. Hemodynamic patterns of agerelated changes in blood pressure. The Framingham Heart Study. Circulation 96:308-315.
10. Franklin S. S, Khan SA, Wong ND, Larson MG, Levy D. 1999. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 100:354-360.
11. Gerhard M., Roddy MA, Creager SJ, Creager MA. 1996. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 27:849-853.
12. Gordon C. L, Chettle DR, Webber CE. 1993. An improved instrument for the in vivo detection of lead in bone. Br J Ind Med 50:637-641.
13. Gurer-Orhan H, Sabir HU, Ozgunes H. 2004. Correlation between clinical indicators of lead poisoning and oxidative stress parameters in controls and lead-exposed workers. Toxicology 195:147-154.
14. Hu H., Aro A, Payton M, Korrick S, Sparrow D, Weiss ST, et al. 1996a. The relationship of bone and blood lead to hypertension. The Normative Aging Study. JAMA 275:1171-1176.
15. Hu H., Milder FL, Burger DE. 1990a. X-ray fluorescence measurements of lead burden in subjects with low-level community lead exposure. Arch Environ Health 45:335-341.
16. Hu H., Payton M, Korrick S, Aro A, Sparrow D, Weiss ST, et al. 1996b. Determinants of bone and blood lead levels among community-exposed middle-aged to elderly men. The Normative Aging Study. Am J Epidemiol 144:749-759.
17. Hu H., Tosteson T, Aufderheide AC, Wittmers L, Burger DE, Milder FL, et al. 1990b. Distribution of lead in human bone: I. Atomic absorption measurements. Basic Life Sci 55:267-274.
18. Khalil-Manesh F, Gonick HC, Weiler EW, Prins B, Weber MA, Purdy R.E. 1993. Lead-induced hypertension: possible role of endothelial factors. Am J Hypertens 6:723-729.
19. Kim R., Aro A, Rotnitzky A, Amarasiriwardena C, Hu H. 1995. K x-ray fluorescence measurements of bone lead concentration: the analysis of low-level data. Phys Med Biol 40:1475-1485.
20. Kwagyan J., Tabe CE, Xu S, Maqbool AR, Gordeuk VR, Randall OS. 2005. The impact of body mass index on pulse pressure in obesity. J Hypertens 23:619-624.
21. Lakatta E.G. 2003. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation 107:490-497.
22. Lakatta E. G, Levy D. 2003. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation 107:139-146.
23. Mahmud A., Feely J. 2003. Effect of smoking on arterial stiffness and pulse pressure amplification. Hypertension 41:183-187.
24. Malvezzi C. K, Moreira EG, Vassilieff I, Vassilieff VS, Cordellini S. 2001. Effect of L-arginine, dimercaptosuccinic acid (DMSA) and the association of L-arginine and DMSA on tissue lead mobilization and blood pressure level in plumbism. Braz J Med Biol Res 34:1341-1346.
25. Menke A., Muntner P, Batuman V, Silbergeld EK, Guallar E. 2006. Blood lead below 0.48 {micro}mol/L (10 {micro}g/dL) and mortality among US adults. Circulation 114:1388-1394.
26. Mitchell G. F, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, et al. 2004. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension 43:1239-1245.
27. Miyagi T., Muratani H, Kimura Y, Fukiyama K, Kawano Y, Fujii J, et al. 2002. Increase in pulse pressure relates to diabetes mellitus and low HDL cholesterol, but not to hyperlipidemia in hypertensive patients aged 50 years or older. Hypertens Res 25:335-341.
28. Muntner P., Menke A, DeSalvo KB, Rabito FA, Batuman V. 2005. Continued decline in blood lead levels among adults in the United States: the National Health and Nutrition Examination Surveys. Arch Intern Med 165:2155-2161.
29. Nash D., Magder L, Lustberg M, Sherwin RW, Rubin RJ, Kaufmann R. B, et al. 2003. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. JAMA 289:1523-1532.
30. Navas-Acien A, Silbergeld EK, Guallar E, Rothenberg SJ. 2007. Lead exposure and cardiovascular disease-a systematic review. Environ Health Perspect 115:472-482.
31. Nawrot T. S, Thijs L, Den Hond EM, Roels HA, Staessen JA. 2002. An epidemiological re-appraisal of the association between blood pressure and blood lead: a meta-analysis. J Hum Hypertens 16:123-131.
32. Ni Z., Hou S, Barton CH, Vaziri ND. 2004. Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells. Kidney Int 66:2329-2336.
33. O'Rourke MF, Hashimoto J. 2007. Mechanical factors in arterial aging. J Am Coll Cardiol 50:1-13.
34. Pirkle J. L, Brody DJ, Gunter EW, Kramer RA, Paschal DC, Flegal KM, et al. 1994. The decline in blood lead levels in the United States. The National Health and Nutrition Examination Surveys (NHANES). JAMA 272:284-291.
35. Safar M. E, Levy BI, Struijker-Boudier H. 2003. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107:2864-2869.
36. Schober S. E, Mirel LB, Graubard BI, Brody DJ, Flegal KM. 2006. Blood lead levels and death from all causes, cardiovascular disease, and cancer: results from the NHANES III mortality study. Environ Health Perspect 114:1538-1541.
37. Schroeder H. A, Tipton IH. 1968. The human body burden of lead. Arch Environ Health 17:965-978.
38. Schwartz J. 1991. Lead, blood pressure, and cardiovascular disease in men and women. Environ Health Perspect 91:71-75.
39. Schwartz J. 1995. Lead, blood pressure, and cardiovascular disease in men. Arch Environ Health 50:31-37.
40. Staessen J. A, Bulpitt CJ, Fagard R, Lauwerys RR, Roels H, Thijs L, et al. 1994. Hypertension caused by low-level lead exposure: myth or fact? J Cardiovasc Risk 1:87-97.
41. Touyz R.M. 2004. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 44:248-252.
42. van Dijk R, van Ittersum FJ, Westerhof N, van Dongen EM, Kamp O., Stehouwer CD. 2002. Determinants of brachial artery mean 24 h pulse pressure in individuals with Type II diabetes mellitus and untreated mild hypertension. Clin Sci (Lond) 102:177-186.
43. Vaziri N.D. 2002. Pathogenesis of lead-induced hypertension: role of oxidative stress. J Hypertens 20(suppl 3):S15-S20.
44. Vaziri N. D, Ding Y. 2001. Effect of lead on nitric oxide synthase expression in coronary endothelial cells: role of superoxide. Hypertension 37:223-226.
45. Vaziri N. D, Ding Y, Ni Z. 1999a. Nitric oxide synthase expression in the course of lead-induced hypertension. Hypertension 34:558-562.
46. Vaziri N. D, Ding Y, Ni Z. 2001. Compensatory up-regulation of nitric-oxide synthase isoforms in lead-induced hypertension; reversal by a superoxide dismutase-mimetic drug. J Pharmacol Exp Ther 298:679-685.
47. Vaziri N. D, Ding Y, Ni Z, Gonick HC. 1997. Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: effect of lazaroid therapy. Kidney Int 52:1042-1046.
48. Vaziri N. D, Liang K, Ding Y. 1999b. Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension. Kidney Int 56:1492-1498.
49. Vaziri N. D, Lin CY, Farmand F, Sindhu RK. 2003. Superoxide dismutase, catalase, glutathione peroxidase and NADPH oxidase in lead-induced hypertension. Kidney Int 63:186-194.
50. Vaziri N. D, Sica DA. 2004. Lead-induced hypertension: role of oxidative stress. Curr Hypertens Rep 6:314-320.
51. Victery W., Vander AJ, Shulak JM, Schoeps P, Julius S. 1982. Lead, hypertension, and the renin-angiotensin system in rats. J Lab Clin Med 99:354-362.
52. Vupputuri S., He J, Muntner P, Bazzano LA, Whelton PK, Batuman V. 2003. Blood lead level is associated with elevated blood pressure in blacks. Hypertension 41:463-468.
53. Willett W. C, Sampson L, Browne ML, Stampfer MJ, Rosner B, Hennekens C. H, et al. 1988. The use of a self-administered questionnaire to assess diet four years in the past. Am J Epidemiol 127:188-199.
54. Williams B., Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D., et al. 2006. Differential impact of blood pressurelowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113:1213-1225.
55. Ye X. B, Fu H, Zhu JL, Ni WM, Lu YW, Kuang XY, et al. 1999. A study on oxidative stress in lead-exposed workers. J Toxicol Environ Health A 57:161-172.